Alnylam reports strong Q2 sales and promising Huntington’s drug data, stock seen with 64% upside potential.

Alnylam Pharmaceuticals announced a 105.7% year-on-year increase in Q2 sales of its drug Amvuttra, reaching about $1.1 billion. The company also shared encouraging clinical data for brezosiran, a treatment under development for Huntington’s disease. Wall Street analysts have set an average price target of $367.78 for Alnylam’s stock, suggesting a potential 64.17% gain. These developments highlight Alnylam’s strong position in RNAi therapeutics and its attractive long-term investment potential.

Alnylam Pharmaceuticals trades at USD 226.24 on Pluang as of Oct 26, 2026 20:32 WIB, up 0.99% for the day. The stock’s market cap stands at $29.98 billion, reflecting strong investor interest. Despite recent gains, ALNY remains well below its 52-week high of $481.59, showing room for growth in the health sector.